跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
歐 穎謙
Doctor
泌尿部
電子郵件
n046797
mail.hosp.ncku.edu
tw
h-index
94
引文
6
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2018
2025
每年研究成果
概覽
指紋
網路
研究成果
(17)
類似的個人檔案
(6)
指紋
查看啟用 Ying-Chien Ou 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Voiding Dysfunction
100%
Botulinum Toxin A
78%
Urine Incontinence
70%
Enuresis
70%
Overactive Bladder
66%
Combination Therapy
57%
Randomized Controlled Trial
57%
Clostridium Botulinum Type A
50%
Obstruction
50%
Transitional Cell Carcinoma
50%
Postmenopause
50%
Tumor Necrosis
50%
Predictive Factor
50%
Telehealth
50%
Micropapillary
50%
Lymphocyte
50%
Sphincter
50%
Sequential Analysis
50%
Meta-Analysis
50%
Physiotherapy
50%
Risk Stratification
50%
Kegel Exercise
42%
International Prostate Symptom Score
33%
Atropine Methyl Bromide
30%
Detrusor
28%
Kidney Preservation
25%
Urinary Tract Function
25%
Urinary Tract Infection
24%
Urodynamics
23%
Attributable Risk
20%
Recurrence Free Survival
18%
Neoplasm
18%
Lower Urinary Tract Symptom
16%
Pelvic Floor
14%
Bladder
14%
Malignant Neoplasm
12%
Bladder Neck Stenosis
11%
Quality of Life
10%
Prostaglandin E Receptor 1
10%
Adverse Event
10%
Hematuria
10%
Systematic Review
10%
Patient-Reported Outcome
10%
Catheterization
10%
Micturition
8%
Therapy Effect
8%
Urge Incontinence
8%
Urethral Catheterization
8%
Recovery from Spinal Cord Injury
8%
Urinary System
7%
Keyphrases
Voiding Dysfunction
50%
Overactive Bladder Symptom Score (OABSS)
50%
Meta-analysis
50%
SMARCB1
50%
Rhabdoid Features
50%
Laser Photoselective Vaporization
50%
Photoselective Vaporization of the Prostate
50%
Benign Prostatic Obstruction
50%
Adjunction
50%
Botulinum Neurotoxin (BoNT)
50%
Ureterectomy
50%
Substitution Therapy
50%
Randomized Controlled Trial
50%
Clinical Analysis
50%
Successful Treatment Outcome
50%
INI1
50%
Intravesical Injection
50%
Ureteral Substitution
50%
Micropapillary Urothelial Carcinoma
50%
Confidence Interval
40%
Intradetrusor Injection
30%
Ureteral Urothelial Carcinoma
25%
Long-term Oncological Outcomes
25%
Intravesical Botulinum Toxin
25%
Post-void Residual
22%
Risk Difference
20%
Subjective Success
20%
Urinary Incontinence
20%
Bladder Diary
18%
Bladder Outlet Surgery
16%
Bladder Voiding Efficiency
14%
Neurogenic Voiding Dysfunction
14%
Renal Preservation
12%
Upper Urinary Tract Recurrence
12%
Renal Sparing
12%
Urine Storage
12%
Older Adult Population
12%
Spinal Cord Injury Rehabilitation
12%
Micropapillary
11%
InvA
10%
Differentia
10%
Urinary Tract Infection
10%
CINAHL
10%
Required Sample Size
10%
Primary Renal Cell Carcinoma
10%
Outcome-based
10%
Older Adults
10%
Hematuria
10%
Systematic Meta-analysis
10%
Treatment Options
10%
Pharmacology, Toxicology and Pharmaceutical Science
Botulinum Toxin A
100%
Clostridium Botulinum Type A
50%
Randomized Controlled Trial
50%
Overactive Bladder
50%
Lower Urinary Tract Symptom
50%
Spinal Cord Injury
50%
Botulinum Toxin
50%
Urinary Tract Infection
42%
Bladder Neck Stenosis
33%
Atropine Methyl Bromide
30%
Urine Incontinence
27%
Enuresis
27%
Clinical Trial
14%
Combination Therapy
12%
Adverse Event
10%
Hematuria
10%
Urge Incontinence
8%
Deterioration
7%
Therapeutic Effect
7%
